A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
Margaret K. Callahan
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Bristol-Myers Squibb
Research Funding - AstraZeneca; Bristol-Myers Squibb
Patrick Alexander Ott
No relevant relationships to disclose
Kunle Odunsi
Research Funding - MedImmune
Stephane V. Bertolini
Employment or Leadership Position - Ludwig Institute for Cancer Research
Research Funding - MedImmune
Linda S. Pan
Employment or Leadership Position - Ludwig Institute for Cancer Research
Ralph Rudolph Venhaus
Research Funding - MedImmune
Joyson Joseph Karakunnel
Employment or Leadership Position - MedImmune
Stock Ownership - MedImmune
F. Stephen Hodi
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Jedd D. Wolchok
Consultant or Advisory Role - MedImmune
Research Funding - MedImmune
Other Remuneration - MedImmune